Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Fenoglio, Roberta, Sciascia, Savino, Beltrame, Giulietta, Mesiano, Paola, Ferro, Michela, Quattrocchio, Giacomo, Menegatti, Elisa, Roccatello, Dario
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Research Paper: Immunology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://ncbi.nlm.nih.gov/pubmed/29989000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25612
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge